Trastuzumab deruxtecan for HER2-low metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You will sign and date the main consent form before any study steps.
- You must provide a new or stored biopsy sample from your breast tumor (primary or metastatic site).
- Your breast cancer must be metastatic or not removable by surgery, and be HER2-low (IHC 1+ or IHC 2+ with negative test) or HER2 IHC 0.
- Your cancer must not have been HER2-positive before (no prior IHC 3+ or IHC 2+ with positive test) and you must not have had anti-HER2 treatment for metastatic disease before.
- You must have had 1–2 previous treatment lines for metastatic breast cancer (with specific rules for some hormone-receptor–positive groups).
- You must have at least one measurable tumor spot on scan, and your heart test (ejection fraction) must be at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.